<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970940</url>
  </required_header>
  <id_info>
    <org_study_id>20DM10201</org_study_id>
    <nct_id>NCT04970940</nct_id>
  </id_info>
  <brief_title>The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2</brief_title>
  <official_title>An Open-label, Multiple Dose, Crossover Study to Evaluate the Drug-drug Interaction Between AJU-A51R1 and AJU-A51R2 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AJU Pharm Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AJU Pharm Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate a pharmacokinetic drug interaction between AJU-A51R1 and AJU-A51R2 in healthy&#xD;
      male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to investigate drug-drug interaction between AJU-A51R1 and AJU-A51R2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2020</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">October 7, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ of AJU-A51R1 and AJU-A51R2</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Area Under Curve tau</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Css,max of AJU-A51R1 and AJU-A51R2</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Cmax, steady state</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>T2DM (Type 2 Diabetes Mellitus)</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment A(AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days)&#xD;
Wash-out for 7 days&#xD;
Period 2: Treatment B(AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days)&#xD;
Period 3: Treatment C(AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A</intervention_name>
    <description>AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <other_name>Period 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B</intervention_name>
    <description>AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <other_name>Period 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C</intervention_name>
    <description>AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <other_name>Period 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Individuals whose age is over 19 and under 65 years old when visiting for initial&#xD;
             screening test.&#xD;
&#xD;
          2. Body mass index(BMI) between 17.5~30.5 kg/m^2 and the body weight must be over 55&#xD;
             kg(men) or 45 kg(women) (Body mass index (BMI) = weight (kg) / height (m)^2) .&#xD;
&#xD;
          3. Individuals with no congenital or chronic disease in three years, no history of&#xD;
             symptoms in internal treatment, or no knowledge in the area.&#xD;
&#xD;
          4. Due to the special characteristics of drugs, the participators must be qualified to do&#xD;
             the clinical screening after examined through hematology test and blood chemistry&#xD;
             analysis, urinary test, the electrocardiogram (ECG), and etc.&#xD;
&#xD;
          5. The participants must be volunteered and sign in an informed consent document proven&#xD;
             by Chonbuk National University IRB before joining a study to show that he was given&#xD;
             informed the purpose of tests and the special characteristics of drugs.&#xD;
&#xD;
          6. Individuals who agreed proper contraception during the study&#xD;
&#xD;
          7. The participants must have an ability and willingness to participate throughout the&#xD;
             entire trials.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Individuals with a medical evidence or a history (excluding dental history of&#xD;
             periodontal surgery, impacted wisdom teeth removal, etc.) of clinically significant&#xD;
             hematological, renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular,&#xD;
             hepatic, psychiatric, neurologic or immune disease.&#xD;
&#xD;
          2. Individual who had a history of gastrointestinal related disease which can be affected&#xD;
             the drug absorption (esophageal achalasia, esophagostenosis, esophageal disease, or&#xD;
             Crohn's disease) or surgeries (except a simple appendectomy or herniotomy).&#xD;
&#xD;
          3. Individual who had following results after examination(a. ALT or AST &gt; twice higher&#xD;
             than Upper limit of normal value).&#xD;
&#xD;
          4. Individual Who constantly intake 210 g/week of alcohol within 6 months of the&#xD;
             screening. (a cup of beer (5%) (250 mL) = 10 g, a shot of soju (20%) (50mL) = 8 g, a&#xD;
             glass of wine (12%) (125 mL) = 12g).&#xD;
&#xD;
          5. Individual whose blood pressure &lt; 90 or ≥160(systolic blood pressure) or &lt; 50 or ≥&#xD;
             100(diastolic blood pressure).&#xD;
&#xD;
          6. Individuals who had been administered investigational product(s) from other clinical&#xD;
             study or bioequivalence study within 180 days prior to the first dose of this&#xD;
             study(except when subject have not taken investigational product(s)).&#xD;
&#xD;
          7. Individual who had a medical history of alcohol and drug abuses.&#xD;
&#xD;
          8. Individual who had taken a drug that has a control of metabolic rate (activation or&#xD;
             inhibition) in 30 days before the first taking of clinical testing drug.&#xD;
&#xD;
          9. Individual who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose&#xD;
             malabsorption or genetic disorders.&#xD;
&#xD;
         10. A person who is not determined unsuitable to participate in this test by the&#xD;
             researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-gul Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jeonbuk University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Min-gul Kim</name>
      <address>
        <city>Jeonju</city>
        <state>Korea</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

